Comparing the current results to its competitors, Sarepta Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by -1.89 %, despite the revenue increase by the most of its competitors of 8.94 %, recorded in the same quarter.
Sarepta Therapeutics Inc 's Comment on Competition and Industry Peers
The company assesses its patent portfolio and strategy to sustain a competitive advantage by analyzing factors including the types of patents filed or pending, the likelihood of product success, market size, the presence of potential competitors, and the enforcement of patent rights. A lack of patents in commercially significant markets may negatively impact the business.
July 19, 2025
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a company specializing in precision genetic medicine for rare diseases, has recently gained attention due to two significant developments. On one hand, the company provided a statement regarding a request from the U.S. Food and Drug Administration (FDA) pertaining to its pioneering gene therapy, ELEVIDYS (delandistrogene moxeparvovec), designed to treat Duchenne muscular dystrophy (Duchenne). On the other hand, the company reported a significant revenue increase in the first quarter of 2025.In its statement, Sarepta indicated that it received an informal request from the FDA at approximately 2:30 p.m. ET to voluntarily cease shipments of ELEVIDYS within the United St...
January 6, 2025
Sarepta Therapeutics: Leading the Charge in Precision Genetic Medicine with Remarkable Growth and Innovation Sarepta Therapeutics, Inc. (NASDAQ: SRPT), an innovative leader in precision genetic medicine focused on rare diseases, is set to showcase its strategic vision and prospective advancements at the prestigious 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Scheduled for January 13, 2025, at 12:00 p.m. E.T. the presentation will provide an insightful overview of Sarepta s progress, featuring a live webcast that will sustain engagement with investors and stakeholders, culminating in a QandA session commencing at 12:20 p.m. E.T.The company’s strong performance in the third qu...
November 26, 2024
Harnessing the Power of Precision Medicine: Sarepta Therapeutics and Arrowhead Pharmaceuticals Forge Strategic Alliance Amidst Record-Breaking Financial Performance Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a trailblazer in the realm of precision genetic medicine for rare diseases, today revealed a major strategic initiative designed to further cement its leadership position in the biotechnology sector. The company has announced an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), a prominent innovator in RNA interference (RNAi) therapeutics. This landmark partnership is poised to significantly enhance Sarepta s portfolio, encompassing multiple clini...
October 1, 2024
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), continues to forge ahead as a paragon in the field of precision genetic medicine for rare diseases. The recent announcements regarding corporate developments, presentation of new data, and financial results underscore the company’s commitment to innovation and growth. This article will delve into these latest strides, showcasing how Sarepta is setting new benchmarks in medical science and corporate performance. Inducement Grants and Workforce Expansion On September 30, 2024, Sarepta Therapeutics granted equity awards to 28 new hires, as part of the company s 2024 Employment Commencement Incentive Plan. These awards were approved by the Compensation Committee of Sar...
September 30, 2024
In the esteemed town of Cambridge, Massachusetts, on the thirtieth day of September in the year of our Lord two thousand and twenty-four, the illustrious institution, Sarepta Therapeutics, Inc. (NASDAQ: SRPT), hath made an announcement of considerable import. Renowned as a paragon in the domain of precision genetic medicine, particularly concerning rare maladies, this distinguished enterprise hath granted equity awards approved by the Compensation Committee of its Board of Directors under the Sarepta 2024 Employment Commencement Incentive Plan. These awards serve as a significant inducement to attract a cadre of 28 talented individuals who commenced their employ with Sarepta during the month of September.It ...
August 7, 2024
Sarepta Therapeutics Reports Significant Milestones and Expands Workforce with New Inducement Grants in Q2 2024 Sarepta Therapeutics, Inc., a pioneer in precision genetic medicine for rare diseases, has published its financial results for the second quarter of 2024, underscoring a transformative period for the company and the field of Duchenne muscular dystrophy (DMD). Headquartered in Cambridge, Massachusetts, Sarepta has consistently positioned itself at the forefront of medical advancements since its inception, and its latest achievements reflect a significant leap toward improving treatment outcomes for patients afflicted by this debilitating condition.In this quarter, Sarepta Therapeutics reported break...
June 1, 2024
Equity Awards Approved as Employment Inducement for New Hires at Sarepta Therapeutics CAMBRIDGE, Mass. - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), renowned for pioneering precision genetic medicine aimed at addressing rare diseases, has recently announced significant equity awards to new hires. This move, aligned with the company s commitment to attracting top-tier talent, was carried out under Nasdaq Listing Rule 5635(c)(4) and reflects Sarepta s ongoing efforts to reinforce its innovative workforce.On May 31, 2024, Sarepta Therapeutics granted equity awards to nine individuals who joined the company in the same month. These awards were sanctioned by the Compensation Committee of the Board of Directors u...
May 31, 2024
Sarepta Therapeutics, a renowned leader in precision genetic medicine for rare diseases, recently announced the granting of equity awards to new employees hired in May 2024. These awards were approved as a material inducement to employment and aim to support Sarepta s commitment to transforming the lives of patients suffering from rare diseases. This article delves into the details of Sarepta s recent inducement grants and explores their significance for the company s growth and the broader field of rare disease research.Sarepta s Leadership in Precision Genetic MedicineSarepta Therapeutics has established itself as a frontrunner in developing breakthrough genetic medicines targeting rare diseases. Their pre...
April 30, 2024
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), known for its pioneering efforts in precision genetic medicine for rare diseases, recently announced the granting of equity awards to new employees. The awards were approved by the Compensation Committee of Sarepta s Board of Directors under the company s 2024 Employment Commencement Incentive Plan. This move is in accordance with Nasdaq Listing Rule 5635(c)(4), which outlines guidelines for inducement grants as a material inducement for employment.Background:The equity awards were granted on April 30, 2024, and are aimed at attracting and retaining talented individuals hired by Sarepta in April 2024. A total of 24 new employees will benefit from these inducement gr...
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Bausch Health Companies Inc operates through three segments: Bausch + Lomb/International, Salix, and Ortho Dermatologics. The company focuses on developing, manufacturing, and marketing a wide range of pharmaceutical products, medical devices, and over-the-counter products primarily in the areas of eye health, gastroenterology, and dermatology. Bausch Health aims to provide innovative and quality healthcare solutions to improve patients' lives globally.
Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of medical conditions. Their business model revolves around conducting extensive research and development to identify novel molecules and compounds that can address unmet medical needs. By leveraging strategic partnerships, acquisitions, and licensing agreements, they aim to bring these therapies to market and provide valuable treatment options to patients worldwide.
Royalty Pharma Plc operates as a pharmaceutical investment company, focusing on acquiring and managing royalty interests in approved drugs. Their business model primarily revolves around purchasing existing royalty streams in exchange for upfront payments, allowing them to generate ongoing cash flows from the sales of these drugs. They aim to provide liquidity to stakeholders, such as biotech and pharmaceutical companies, by offering a financial alternative to traditional financing options.
Sources:
Sarepta Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Sarepta Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
